Fortress Biotech (FBIO)
(Real Time Quote from BATS)
$1.86 USD
+0.13 (7.51%)
Updated Aug 8, 2024 03:44 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 21 - 40 ( 317 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: The Hits Just Keep Comin? Checkpoint Releases Promising Data in Advanced Cutaneous Cell Carcinoma
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Avenue Therapeutics (ATXI), A Fortress Company, Announces Agreement with the FDA
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Journey Medical - Positive Pivotal Data
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Fortress: $76M in Revenues $181M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Fortress is Down but Fundamentals Are Strong
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Updated Model - Challenging Environment, but Deep Value
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Avenue (ATXI-Not Rated), A ~20% Owned Fortress Company Raises $12M
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Portfolio of Partnered Assets Continues to Build Momentum; Key Regulatory Filings on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: NIAID grant for up to $20M to fund trial of Triplex CMV vaccine
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J